|
|
Personal tools
Title:
|
Assistant Investigator
|
|
Office Address:
|
2425 Stockton Blvd, Room 601
Sacramento, CA 95817
|
Office Phone:
|
(916) 453-5061
|
|
E-Mail Address:
|
athena.soulika (at) ucdmc.ucdavis.edu
|
|
Education:
|
BS Chemistry, U. of Patras, Patras Greece
PhD Immunology/Protein Chemistry,
U. of Patras, Patras Greece/U. of Pennsylvania, Philadelphia
|
|
Research Papers:
|
Click Here for Research Paper Links
|
Research Interests:
Innate immunity, T cell polarization
Current Research:
The main effectors during the axonal demyelinating phases of multiple sclerosis, and its animal model Experimental Autoimmune Encephalomyelitis (EAE) are the activated cells that penetrate the Blood Brain Barrier (BBB). The demyelination of axons leadso neurological deficits and in extreme situations to death. Recently, the subset of cells Th17 has been associated with the pathogenesis of the disease. These cells have been associated with a variety of autoimmune and disorders. However, the mechanisms governing the activation and the polarization of these cells are unclear. The first responder during an infection is the innate immunity. Its response is immediate and upon persistent activation it creates the milieu that will eventually influence the polarization and activation of T cells. We use the well established model of MOG-EAE in mice in order to identify the components of the innate immunity that facilitate the development of the pathogenic T cells during the different stages of the disease.
Noteworthy Publications:
TITLE
|
AUTHOR(s)
|
YEAR
|
DOWNLOAD
|
|
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. In press. J Biol Chem 2009; 00: 00 - 00.
|
Selvaraj V, Soundarapandian M, Chechneva O, Williams AJ, Sidorov MK, Soulika AM, Pleasure DE, Deng W.
|
2009
|
HTML
PDF
|
|
Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. Under Revision. J Neuroscience 2009; 00: 00 - 00.
|
Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure D.
|
2009
|
In Press
|
|
“Skittich ABCA2" knockout mice display tremor hyperactivity, and abnormal myelin ultrastructure in the central nervous. Mol Cell Biol 27:44-53
|
Mack, Beljanski, Soulika, Townsend, Brown, Davis, Tew
|
2007
|
HTML
|
|
Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 55:57-64
|
Bannerman, Hahn, Soulika, Gallo, Pleasure
|
2007
|
HTML
|
|
Inflammation in white matter: clinical and pathophysiological aspects. Mental Retardation Developmental Disabilities Res Rev 12: 141-146
|
Pleasure, Singh, Soulika, Gallo, Bannerman
|
2006
|
HTML
|
|
Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. Mol Immunol. 2006 May;43(12):2023-9
|
Soulika AM, Holland MC, Sfyroera G, Sahu A, Lambris JD.
|
2006
|
HTML
|
|
Characterization of the ATPase activity of human ATP-binding cassette transporter-2 (ABCA2). In Vivo. 2005 Jul-Aug;19(4):657-60.
|
Beljanski V, Soulika A, Tucker JM, Townsend DM, Davis W Jr, Tew KD.
|
2005
|
HTML
|
|
Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim Biophys Acta 1678:22-32
|
Ile, Davis, Boyd, Soulika, Tew
|
2004
|
|
|
Association of ABCA2 expression with determinants of Alzheimer's disease. FASEB J 18:1129-1131
|
Chen, Vulevic, Ile, Soulika, Davis, Reiner, Connop, Nathwani, Trojanowski, Tew
|
2004
|
|
|
Glutathione and ABC transporters as determinants of sensitivity to oxidative and nitrosative stress. J Nutr 134: 3205S-3206S
|
Tew, Boyd, Chen, Davis, Fazilev, Findlay, Gate, Ile, Soulika, Townsend
|
2004
|
|
|
Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. J Immunol. 171:1881-1890
|
Soulika, Morikis, Sarrias, Roy, Spruce, Sahu, Lambris
|
2003
|
|
|
Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunology 96: 212-221
|
Soulika, Khan, Hattori, Bowen, Richardson, Sahu, Edmunds, Lambris
|
2002
|
|
IPRM 2425 Stockton Blvd. Sacramento, CA 95817 (916) 453-2290
webmaster (at) iprmd.org
|